// App-Quantinova.ai

5020 : Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Researchers

Presenter

  • Shahneen Sandhu

Principal Investigators

  • David Olmos

  • Eleni Efstathiou

  • Elena Castro

  • Dana E. Rathkopf

  • Matthew Raymond Smith

  • Guilhem Roubaud

  • Eric Jay Small

  • Andrea Juliana Gomes

  • Marniza Saad

  • Deniz Tural

  • Shibu Thomas

  • Karen Urtishak

  • Michael Gormley

  • Gary Mason

  • Brooke Diorio

  • George C. Wang

  • Angela Lopez-Gitlitz

  • Kim N. Chi

Medical Centers

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

  • Kings College London, London, United Kingdom

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Houston Methodist Cancer Center, Houston, TX

  • University Hospital Virgen de la Victoria (HUVV), Intercentre Clinical Management Unit (UGCI) of Medical Oncology, Málaga, Spain

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • Institut Bergonie, Bordeaux, France

  • University of California, San Francisco, San Francisco, CA

  • Liga Norte Riograndense Contra o Cncer, Natal, Brazil

  • University of Malaya, Kuala Lumpur, Malaysia

  • Bakyrkoy Dr. Sadi Konuk Research Hospital, Istanbul, Turkey

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research and Development, Titusville, NJ

  • Janssen Research & Development, Los Angeles, CA

  • The University of British Columbia, Vancouver, BC, Canada

Locations

  • Australia

  • United Kingdom

  • Spain

  • United States

  • France

  • Brazil

  • Malaysia

  • Turkey

  • Canada

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Urology

  • Genetic Disorder

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Metastatic castration-resistant prostate cancer

  • Fanconi anemia, complementation group A

Biomarkers

  • Prostate specific antigen

  • checkpoint kinase 2

  • Fanconi anaemia, complementation group A

  • Histone Deacetylase 2

  • Hormone receptor

  • Thrombospondin-1

  • Partner and localizer of BRCA2

  • BRCA1 interacting protein

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • CB-7598

  • Prednisone

  • Niraparib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03748641

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved